Перевести на Переведено сервисом «Яндекс.Перевод»

FDA Calendar

Date PDUFA table FDA is very important, because they help you to watch when decisions on main areas will be announced. In addition, as a rule, such reviews make it possible to anticipate key events and their development. Thus, the presence of prior knowledge of the catalyst provides a way to maximize profits or minimize losses trading in the stock of biotechnology companies.
Date Company Event Description Result
Verastem Phase 2 VS-6063, Pleural mesothelioma Failure
Trevena Phase 2b TRV-130, Painkiller Success
TRACON Pharmaceuticals PHASE 2 TRC105, hepatocelluar carcinoma Success
Tetraphase Pharmaceuticals Phase 3 Eravacycline, Complicated urinary tract infections Failure
Synthetic Biologics PHASE 2 SYN-004 (C-IBS) Failure
Spark Therapeutics PHASE 3 SPK-RPE65, inherited retinal dystrohies Success
Sangamo Biosciences PHASE 2 SB-728-1401, HIV/AIDS Success
Raptor Pharmaceuticals PHASE 2 RP-103, fatty liver disease Failure
Radius Health NDA FILING ABALOPARATIDE-SC, osteoporosis Success
Puma Biotechnology PHASE 2 PB272, breast cancer Success
PTC Therapeutics PHASE 3 ATALUREN, Duchenne muscular dystrophy Success
Protalix BioTherapeutics PHASE 1/2 PRX-102, Fabry disease Success
Neurocrine Biosciences PHASE 3 VMAT2 NBI-98854 - KINECT 3, tardive dyskinesia Success
Lipocine NDA FILING LPCN 1021, low testosteron Success
Heron Therapeutics PHASE 2 HTX-011, post-operative pain Success
Heat Biologics PHASE 2 HS-110, cell lung Success
GW Pharmaceuticals PHASE 2 GWP42003, Schizophrenia Success
Genocea Biosciences PHASE 2 GEN-004, universal vaccine agains pneumococcus Failure
Flexion Therapeutics PHASE 2B FX006, osteoarthritis Failure
Apricus Biosciences PHASE 2A RAYVA, secondary Raynaud's phenomenon Success
1 2